UNSPSC 51172322: Dicobalt edetate

This classification denotes a protective agent with the molecular formula C10H12N2O8.2Co, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier UKC6GH80QR, chemically known as cobaltate(2-), ((n,n-1,2-ethanediylbis(n-(carboxymethyl)glycinato))(4-)-n,n,o,o,o(sup n), o(sup n))-, cobalt(2+) (1:1), (oc-6-21) but generally known as dicobalt edetate, which bears US NIH Compound Identifier 71942. European Medicines Agency schedules Dicobalt edetate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13569MIG.

UNSPSC 51172322 Dicobalt edetate, a Commodity code, nominally identifies a specific chelating agent pharmaceutical, but recent state and local solicitations tagged under this code do not reflect procurement of dicobalt edetate itself. Instead, the code appears in notices for broader drug testing and pharmacy benefit services where the chemical may play a subsidiary or unrelated role. State and local buyers soliciting under this code are acquiring offender specimen collection and drug testing services (urine immunoassay and confirmatory testing), generic multi-source pharmaceutical supply agreements, and therapeutic pharmacy program consultation—work that spans county community supervision departments, state health and human services commissions, and multistate cooperative purchasing alliances. The actual procurement focus is on testing logistics, pharmacy benefit management infrastructure, and supply-chain coordination rather than the dicobalt edetate compound itself.

Recent activity centers on Texas and Minnesota. Collin County Community Supervision and Corrections Department issued RFP 2026-327 for offender specimen collection and drug testing services with a July 23, 2026 response deadline and an estimated contract value of $600,000 over two years with optional renewals through five years total; the county seeks vendors to operate two collection sites in the Dallas area, administer a randomized testing notification system, and deliver immunoassay screening with LC/MS/MS or GC/MS confirmation across approximately 25,031 annual tests. The Texas Health and Human Services Commission posted Request for Information HHS0017013 in March 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescription program, with no formal award value disclosed. The Minnesota Department of Administration's Office of State Procurement, administering the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), issued RFP S1070000015802 due March 26, 2026 for generic multi-source pharmaceuticals and OTC products distributed across participating state and local facilities in Minnesota and Oregon, with contract effectiveness July 1, 2026. The code shows minimal recent activity tightly clustered in Texas and Minnesota, with no clear alignment between the nominal commodity (dicobalt edetate) and the services actually being solicited.